Ratings PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
33.01 ^USD	-1.81%		+15.54%	+19.78%

Apr. 30	North American Morning Briefing : More Earnings -2-	DJ
Apr. 29	Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company is in a robust financial situation considering its net cash and margin position.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
With an enterprise value anticipated at 3.09 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PTC THERAPEUTICS, INC.	+19.78%	2.53B	B
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B	B+
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B	B+
ARGENX SE	+4.40%	22.94B	B
BIONTECH SE	-12.15%	22.34B	B+
GENMAB A/S	-4.36%	19.25B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.08B	A-
BEIGENE, LTD.	-10.04%	16.96B	B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B	C+
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes